PEVIA Consortium Submits 1st Intermediate Report
Vevey, 2 July 2018 – The European Biopharmaceutical Enterprises (EBE) has appointed Dr Ahmed Bouzidi, CEO of Vaxeal, as new President.Dr Bouzidi has been a board member of EBE since its inception until 2003, re-joining the EBE Board in 2012.
Ahmed Bouzidi is the founder and Chief Executive Officer of Vaxeal Holding SA, a leading SME pioneer in immuno-oncology. He previously founded and managed the leading biotech pioneers, SEDAC-Therapeutics Inc. and Biophysiomics Holding Inc. He also held senior advisory positions with high-level Chinese healthcare stakeholders, and worked as a senior researcher at the LFB for a decade. Dr Bouzidi holds a Master degree in Animal Biology from University of Lille (France) and a PhD in Cellular Biology and an MBA in Finance from University of New Hampshire, Durham (USA).
The EBE Board leadership is completed with Dr François Martelet, CEO of NetScientific PLC, EBE Vice-President. Didier Malherbe, Vice President Public Affairs at UCB and Managing Director at UCB Belgium, who continues to serve as EBE’s treasurer.
EBE also appointed four new Board members: Erik Bogsch (Deputy Director and Head of R&D and Manufacturing, Biotechnology business unit of Gedeon Richter, for PregLem), Ingmar Hoerr (Co-Founder/Chairman of the Supervisory Board, Curevac AG), Maria Pascual (VP Regulatory Affairs & Corporate QA, TiGenix) and Manos Perros (President & Chief Executive Officer, Entasis Therapeutics).
Michele Antonelli (President, Stallergenes SAS, and Executive Vice President, Head of Europe & International, Stallergenes-Greer), Nicola Beaucamp (Head of Process Research in Pharma Research & Early Development, Roche Diagnostics GmbH), Roberto Gradnik (Chief Executive Officer at Ixaltis), Jochen Maas (General Manager R&D at Sanofi Aventis Germany) and Jacky Vonderscher (Chief Executive Officer at ENYO Pharma SA) have all been re-elected to serve on the board for the 2018-2020 term.
“I would like to thank Eduardo Bravo and Andrea Chiesi, the previous president and vice-president, for their great job over the past two years. I am honoured to take on this role at such an important time for EBE. I very much look forward to working with François and our colleagues to tackle the many exciting opportunities and challenges being presented by the biopharmaceutical industry in Europe”, said Ahmed Bouzidi,PhD, CEO of Vaxeal.
To see the EBE Governance page, please click here.
European Biopharmaceutical Enterprises (EBE) represents the voice of biopharmaceutical companies of all sizes in Europe and is a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA). It currently has 56 members – the majority of which are small and medium sized companies – engaged in the research, development, manufacturing and marketing of new medicinal products using biotechnology.
Vaxeal Holding SA is headquartered in Vevey, Switzerland. The company, in partnership with leading international research institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families and initial programs have reached the pre-clinical stage in major disease segments. Visit www.vaxeal.net for more information.